Dr. Freedman is a professor of medicine at Harvard Medical School and at Dana-Farber Cancer Institute (DFCI) in the Department of Medical Oncology and attending physician at Brigham and Women's Hospital. He is the clinical director of the Lymphoma Program at DFCI. Dr. Freedman has focused on clinical and laboratory research in non-Hodgkin lymphomas. A graduate of Brandeis University, Dr. Freedman received his MD from University of Massachusetts Medical School, and came to Dana-Farber as a fellow in medical oncology in 1982.
Dr. Freedman's research interests have focused on the development of new therapies for non-Hodgkin lymphoma. This research includes efforts toward enhancing the effects of antibody based therapies and understanding how the tumor microenvironment can be manipulated in the treatment of lymphomas.